ストックスクリーナーアプリを入手
5.59
4.88%
0.26
前日終値:
$5.33
開ける：
$5.34
24時間の取引高:
73,064
Relative Volume:
0.97
時価総額：
$17.93M
収益：
-
当期純損益:
$-37.68M
株価収益率:
-0.4723
EPS:
-11.8364
ネットキャッシュフロー:
$-30.65M
1週間 パフォーマンス:
-0.18%
1か月 パフォーマンス:
+9.18%
6か月 パフォーマンス:
-40.78%
1年 パフォーマンス:
+1,331%
1日の値動き範囲:
$5.27
$5.65
1週間の範囲:
$5.27
$5.9387
52週間の値動き範囲:
$0.3195
$20.00
Passage Bio Inc Stock (PASG) Company Profile
名前
Passage Bio Inc
セクター
電話
(267) 866-0312
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
5.59 | 17.93M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-04-21 | ダウングレード | Wedbush | Outperform → Neutral |
| 2026-03-31 | 開始されました | Oppenheimer | Outperform |
| 2026-02-10 | 再開されました | Chardan Capital Markets | Buy |
| 2024-11-29 | 再開されました | Wedbush | Outperform |
| 2024-09-03 | 開始されました | Rodman & Renshaw | Buy |
| 2022-03-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-19 | ダウングレード | Goldman | Buy → Neutral |
| 2021-07-01 | 開始されました | Raymond James | Outperform |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-03-04 | アップグレード | Goldman | Neutral → Buy |
| 2021-02-04 | 開始されました | Guggenheim | Buy |
| 2021-01-25 | 開始されました | Wedbush | Outperform |
| 2021-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-11 | 開始されました | Citigroup | Neutral |
| 2020-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-25 | ダウングレード | Goldman | Buy → Neutral |
| 2020-03-25 | 開始されました | Chardan Capital Markets | Buy |
| 2020-03-24 | 開始されました | Cowen | Outperform |
| 2020-03-24 | 開始されました | Goldman | Buy |
| 2020-03-24 | 開始されました | JP Morgan | Overweight |
すべてを表示
Passage Bio Inc (PASG) 最新ニュース
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Passage Bio Inc (PASG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Passage Bio Inc (PASG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sea Limited’s Shopee Order Growth Reinforces E-Commerce MomentumEarnings Momentum Score - newsline.com
Fierce Biotech Layoff Tracker 2026: enGene halves workforce; Neumora cuts 35% - Fierce Biotech
PRS Q1 2026 Earnings: Solid EPS Beat Driven by Core OperationsEarnings Deceleration Risk - newsline.com
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
Passage Bio Inc. (PASG) Surges Over 9% as Biotech Stock Tests Key ResistanceEarnings Quality Factor - newsline.com
Gartner (IT) Q1 2026 Earnings: EPS Surprises to the Upside Despite Modest Stock PullbackRevenue Recognition Risk - newsline.com
Guggenheim Downgrades Passage Bio(PASG.US) to Hold Rating - Moomoo
Passage Bio (PASG) Downgraded to Neutral as Strategic Review Ini - GuruFocus
Passage Bio (PASG) Slides 6.33% as Stock Approaches Key Support at $5.34SuperTrend - newsline.com
Thryv Holdings Faces Continued Pressure as Shares Slide to $3.72Dollar Neutral Pair - newsline.com
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Thera - Barchart.com
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SentimentGAAP Earnings Report - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentAnalyst Consensus Shift - newsline.com
Passage Bio Inc. (PASG) Edges Higher as Buyers Defend Key Support LevelCumulative Volume - The Legal Advocate
Passage Bio Inc. (PASG) Shows Modest Gains Amid Consolidation Near Key LevelsHigh Low Breadth - newsline.com
Unusual Machines (UMAC) Surges 57% as Momentum Builds Above Key SupportInstitutional Sentiment - The Legal Advocate
Passage Bio Ends Gemma Collaboration, Philadelphia Office Lease - Moomoo
Passage Bio Ends Key Collaborations and Office Lease - TipRanks
Passage Bioterminates research, collaboration and license agreement with Gemma Bio Therapeutics - marketscreener.com
Passage BIOTerminates Research, Collaboration And License Agreement With Gemma BIO Therapeutics - TradingView
Passage Bio (NASDAQ: PASG) ends Gemma deal, pays $2.3M to exit lease - Stock Titan
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-Than-Expected Loss Fuels Share GainsOne-Time Gain Impact - newsline.com
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Market ReactionUpward Estimate Revision - The Legal Advocate
PASG Q1 2026 Earnings: Smaller-than-Expected Loss Drives Positive Market ResponseEarnings Volatility Report - The Legal Advocate
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio Shareholders Approve Directors and Executive Pay - TipRanks
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
PASG Technical Analysis & Stock Price Forecast - Intellectia AI
Barnes & Noble Education Inc (BNED) Surges 6.36%: Key Levels to WatchWMA Signal - newsline.com
PASG Q1 2026 Earnings: Narrower-than-expected loss lifts sharesAnalyst Consensus Shift - thelegaladvocate.com
Passage Bio Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentCEO Earnings Statement - The Legal Advocate
PASG Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Operational ProgressCrowd Sentiment Entry - Newser
Passage Bio Inc. (PASG) Holds Steady Near Support as Biotechnology Sector Faces HeadwindsBeta Neutral Pair - Newser
Director Sondhi Dolan receives 10,539 Passage BIO (PASG) stock options - Stock Titan
Passage BIO (NASDAQ: PASG) director Derrell Porter receives grant of 10,539 stock options - Stock Titan
Passage BIO, Inc. (PASG) director gets 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director Sandip Kapadia awarded 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) director receives 10,539 stock options at $5.08 - Stock Titan
Passage BIO (PASG) awards 10,539 options to director at $5.08 - Stock Titan
Passage Bio Inc stock (US70267E1055): gene therapy developer back in focus after recent moves - AD HOC NEWS
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Passage Bio Inc stock (US70267E1055): gene therapy hopes meet analyst caution - AD HOC NEWS
Gene Therapy In CNS Disorder Therapeutics Market Size in the 7MM - openPR.com
Passage Bio Inc (PASG) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):